Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLAS trial of apalutamide with GnRH agonist and radiotherapy in high-risk localized or locally advanced prostate cancer
MOH_2017-03-19_000254Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of apalutamide in prostate cancer (PCa) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Metastasis-free survival. Started Feb 2016; status: active, not recruiting.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on MOH_2017-03-19_000254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-19_000254.